Current issues in ovarian cancer

Current issues highlight some of the latest research into ovarian cancer, new therapies becoming available and new drug treatments coming to the market.

Platinum/taxol chemotherapy is best for advanced ovarian cancer Ovarian cancer patients are more likely to achieve a good first time chemotherapy remission with a combination of taxol and cis-platiun (or carboplatin) than a combination of cis-platinum and...
Salvage chemotherapy in ralpsed ovarian cancer Optimal 'salvage' chemotherapy in patients with relapsed ovarian following front line chemotherapy. The question as to the optimal therapy for patients, who relapse following first line therapies in...
Intraperitoneal radio-immunotherapy in ovarian cancer A murine monoclonal antibody, that recognises a repeated epitope of a tumour associated antigen present on the surface of over 90% of ovarian cancer cells, has been used as therapy by instillation...
Aspirin may lower the risk of ovarian cancer At the recent 32nd meeting of the American Society of Gynecological Oncology, data were presented that suggests that aspirin may lower the incidence of ovarian cancer. In a cohort of 748 women...
Glutamine may reduce the severity of Paclitaxel (taxol) peripheral neuropathy Paclitaxel (taxol) is a very powerful tool for the oncologist, having a very active role in primary management of ovarian cancer and others (e.g. breast cancer). However, a peripheral neuropathy...
Pegylated Liposomal Doxorubicin versus Topotecan chemotherapy for relapsed ovarian cancer Although the first line of chemotherapy for advanced ovarian cancer is well established (namely taxol and platin), for patients who relapse the optimal alternative chemotherapy is still debated. In a...
Brca gene mutations and survival in ovarian cancer sufferers In an Israeli study (J Clin Oncol 20: 463-66; 2002) the outcomes of 234 women presenting with ovarian cancer and harbouring a mutation of the oncogene BRCA family were compared with the outcomes in...
Novel Glutathione leads to longer remission in ovarian cancer Previously treated ovarian cancer patients, who have failed after first line drugs such as taxol and platins, represebnt a difficult type of patient to successfully treat. Conventional agents such as...